News.

Project Quantico is the working name for SGNL Technologies' third venture. It is early, it is in active development, it is funded, and this page is the first public description of what it is.

Designing a drug means predicting how a molecule will behave — how it folds, what it binds to, how tightly, and what it does once it gets there. Those behaviours are governed by quantum mechanics: the physics of electrons, which do not follow the rules that everyday objects do.

Classical computers cannot simulate that physics exactly. The cost of an exact simulation grows exponentially with the number of electrons, so beyond a handful of atoms it becomes impossible — not slow, impossible. The entire field runs on approximations instead, and every approximation is a place where a prediction can quietly go wrong.

The organisations that feel this most are the ones with the least compute: emerging biotechs, academic labs, and rare-disease foundations. The computational chemistry that large pharmaceutical companies treat as routine infrastructure is, for them, out of reach.

A quantum computer stores information in quantum states, which means it can represent the behaviour of electrons directly rather than approximating it. Simulating a quantum system on quantum hardware is, in principle, the natural way round.

That principle is not new. What is changing is that quantum hardware has become real enough to run these calculations, and the software layer between a chemist's question and a quantum processor is still largely missing. That layer is what we are building.

We would rather be accurate than impressive, so plainly: Quantico is at prototype stage, and quantum chemistry today is not curing anything.

What we have working is an end-to-end toolchain — from a molecule's structure through to a quantum calculation and back — validated on small molecules where the exact answer is already known, and executed on real quantum hardware rather than only on simulators. Matching a known answer is not a discovery; it is the evidence that the pipeline is correct.

The honest limit is scale. Molecules of genuine pharmaceutical interest remain out of reach of current hardware, and no amount of software fixes that. What software can do is be ready — so that the day the hardware crosses the threshold, the infrastructure to use it already exists and is not another decade of work.

Quantico is the infrastructure layer: molecular data pipelines, the quantum chemistry runtime, hardware access, and an interface that a research scientist can use without becoming a quantum programmer first.

Much of that stack is useful before any quantum advantage arrives. Molecular property analysis, binding data, and comparison tooling are classical problems that the same platform solves today, which is how the work stays grounded in real research rather than in a promise.

On 8 August 2026, SGNL Technologies raised $5,000,000 in pre-seed funding to build Quantico.

The round is committed to two things. The first is research and development: the quantum chemistry runtime, the molecular data pipelines, and the long unglamorous work of making a scientific tool trustworthy enough that someone would base a decision on it.

The second is people. This problem sits at the intersection of quantum computing, computational chemistry, and infrastructure engineering, and very few individuals hold all three. Assembling a team that collectively does is the harder half of the work, and most of what the money is for.

The goal is to make drug-development infrastructure available to organisations that have the science but not the compute budget — emerging biotechs, academic groups, and the foundations working on conditions too small to attract a major pharmaceutical programme.

It matters most for the diseases that fall hardest on the people least able to fund research into them. Malaria and HIV are the reason this project exists rather than some easier one: the science there is difficult, the need is not in question, and the economics have never worked the way they do for conditions in wealthier markets.

Project Quantico is in development and not yet available. If you are working in this space and want to follow the work or talk about early access, we would like to hear from you.